Accuray Incorporated (ARAY)
- Previous Close
1.7000 - Open
1.7500 - Bid 1.7300 x 200
- Ask 1.7600 x 200
- Day's Range
1.7250 - 1.7700 - 52 Week Range
1.4000 - 3.1000 - Volume
457,425 - Avg. Volume
927,285 - Market Cap (intraday)
175.469M - Beta (5Y Monthly) 1.41
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1600 - Earnings Date Nov 5, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.13
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
www.accuray.comRecent News: ARAY
View MorePerformance Overview: ARAY
Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARAY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARAY
View MoreValuation Measures
Market Cap
174.47M
Enterprise Value
316.64M
Trailing P/E
--
Forward P/E
86.96
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.38
Price/Book (mrq)
3.87
Enterprise Value/Revenue
0.71
Enterprise Value/EBITDA
55.46
Financial Highlights
Profitability and Income Statement
Profit Margin
-3.48%
Return on Assets (ttm)
0.41%
Return on Equity (ttm)
-31.49%
Revenue (ttm)
446.55M
Net Income Avi to Common (ttm)
-15.54M
Diluted EPS (ttm)
-0.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
116.37M
Total Debt/Equity (mrq)
289.67%
Levered Free Cash Flow (ttm)
380k